Australia markets close in 3 hours 14 minutes

Recce Pharmaceuticals Ltd (RCE.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.6400-0.0200 (-3.03%)
As of 12:28PM AEST. Market open.
Currency in AUD

Valuation measures4

Market cap (intra-day) 134.61M
Enterprise value 130.80M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)251.99
Enterprise value/revenue N/A
Enterprise value/EBITDA -12.40

Trading information

Stock price history

Beta (5Y monthly) 1.27
52-week change 37.51%
S&P500 52-week change 323.57%
52-week high 30.7772
52-week low 30.4100
50-day moving average 30.4848
200-day moving average 30.5136

Share statistics

Avg vol (3-month) 3172.76k
Avg vol (10-day) 3247.63k
Shares outstanding 5203.95M
Implied shares outstanding 6203.95M
Float 8130.89M
% held by insiders 138.49%
% held by institutions 17.43%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 June 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -167.74%
Operating margin (ttm)-303.45%

Management effectiveness

Return on assets (ttm)-167.19%
Return on equity (ttm)-1,277.62%

Income statement

Revenue (ttm)6.75M
Revenue per share (ttm)0.04
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -10.68M
Net income avi to common (ttm)-11.32M
Diluted EPS (ttm)-0.0600
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)4.01M
Total cash per share (mrq)0.02
Total debt (mrq)2.43M
Total debt/equity (mrq)455.33%
Current ratio (mrq)1.04
Book value per share (mrq)0.00

Cash flow statement

Operating cash flow (ttm)-9.01M
Levered free cash flow (ttm)-6.21M